A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.


Updates from The Motley Fool

Latest updates on Sarepta Therapeutics from Fool.com.  The Fool has written over 300 articles on Sarepta Therapeutics.


Stock Performance

View Interactive SRPT Charts
Sponsored by

Key Data Points

Primary metrics and data points about Sarepta Therapeutics.
Current Price: $52.60
Prev Close: $53.65
Open: $53.71
Bid: $52.01
Ask: $53.00
Day's Range: $52.10 - $54.06
52wk Range: $26.26 - $57.57
Volume: 2,403,598
Avg Vol 1,749,655
Market Cap: $3B
P/E (ttm): -25.19
EPS (ttm): ($2.13)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Sarepta Therapeutics.
CAPS Rating 2 out of 5
 
284 Outperform
50 Underperform
CAPS All Stars
 
44 Outperform
12 Underperform

How do you think Sarepta Therapeutics will perform against the market?



You pick for Sarepta Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Douglas S. Ingram, CEO

100% Approve

Based on 1 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Sarepta Therapeutics.

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers